Pipeline
Pipeline Programs
EB-003
Prescription Model
Highlights
-
Moderate dose
-
Prescription model
-
Taken regularly
-
Minimal side effects and reduced hallucinations
-
Available to a large patient population
EB-003 is a novel neuroplastogen that engages both the 5-HT2A and 5-HT1B receptors, a dual mechanism that may define a new class of neuropsychiatric treatments. This unique pharmacological profile is designed to promote adaptive rewiring of brain circuits while stabilizing emotional and behavioral regulation — potentially enabling durable recovery in patients with post-traumatic stress disorder (PTSD), treatment-resistant depression, and generalized anxiety. Pre-IND results suggest a fast-acting, well-tolerated, non-hallucinogenic therapy for patients underserved by current options, positioning EB-003 as a differentiated candidate in the competitive mental health space.
Key Investment Highlights
- Differentiated mechanism: Dual engagement of 5-HT2A and 5-HT1B receptors
- Large addressable market: Multiple high-burden psychiatric conditions with limited effective treatments
- Compelling preclinical profile: Fast-acting, durable, and non-hallucinogenic
- Convenience: Oral administration, no in-clinic dosing required
- Favorable safety signals: Reduced hallucination risk and improved cardiac safety
EVM401
Enveric’s EVM401 series consists of novel phenylalkylamines and indolethylamines, including mescaline-derived compounds, that demonstrate promising interactions with key brain receptors involved in mental health disorders and addiction. Mescaline is a naturally occurring psychedelic alkaloid found in certain cacti, such as peyote and San Pedro, known for its ability to alter perception, cognition, and mood. Early research suggests these compounds may have the potential to help manage opioid withdrawal, attention-deficit/hyperactivity disorder (ADHD), anxiety, depression, and substance use disorders by targeting receptors linked to these conditions.
While Enveric’s primary focus remains on advancing EB-003 toward clinical trials, advancing the EVM401 series reinforces the Company’s commitment to expanding its pipeline and driving innovation in mental health treatment.
